Compass Therapeutics Provides Corporate Update
We continue to open clinical sites and enroll patients in COMPANION-002, the Phase 2/3 randomized study of CTX-009 in patients with advanced biliary tract cancer . Consistent with prior guidance, top...
Source: marketscreener.com